

Biosimilars Litigation and Client Counseling

Published by The American Bar Association

March 18, 2025

Four of Katten's Intellectual Property attorneys co-authored a chapter of "Biosimilars Litigation and Client Counseling," published by The American Bar Association (ABA), under the section titled "Advising Clients on Product Strategies, Global Considerations, and the Future of BPCIA and Biosimilars." New York Partners Deepto Mukerjee, Intellectual Property department chair, and Lance Soderstrom, Patent Litigation co-chair, along with Chicago Counsel Matthew Holub and Dallas Associate Jillian Schurr, wrote a chapter about product case studies that delves into matters related to Abbvie's Humira® (adalimumab), Amgen's Neupogen® (filgrastim)/Neulasta® (pegfilgrastim) and Genentech's Herceptin® (trastuzumab). Deepto and Lance also contributed as associate editors on the book's Board of Editors.

The ABA describes "Biosimilars Litigation and Client Counseling" as a thorough guide "to the field of biologic products and biosimilars, as well as the laws governing them," including the Biologics Price Competition and Innovation Act. The book intends to provide attorneys, judges, and pharmaceutical managers or decision-makers with a comprehensive reference and useful analysis of legal processes and challenges in this area, summarizing both the statutory and regulatory framework for applying for and receiving a biologic and biosimilar application.

["Biosimilars Litigation and Client Counseling,"](#) The American Bar Association, June 17, 2024

CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



Deepro R. Mukerjee

+1.212.940.8552


deepro.mukerjee@katten.com



Lance A. Soderstrom

+1.212.940.6330

lance.soderstrom@katten.com



Matthew M. Holub

+1.312.902.5326

matthew.holub@katten.com



Jillian M. Schurr-Hendrix

+1.214.765.3684

jillian.schurr-hendrix@katten.com

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2026 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at katten.com/disclaimer.